P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

July 2005

Features

Systematic Literature Review of the Economics of Intravenous Patient-Controlled Analgesia

Most published studies of IV PCA do not include the full range of costs associated with this therapy. The author reviews some of the important cost drivers.
Alex Macario, MD, MBA

Short-Term and Long-Term Effects of Bisoprolol on Chronic Heart Failure Related to Rheumatic Heart Disease and Atrial Fibrillation

Bisoprolol appears to have the potential to improve New York Heart Association class and exercise tolerance in patients with heart failure.
Maoqin Shu, MD, Ruixia Xi, PhD, Ping Zhang, MD, Guoxiang He, PhD, Zhiyuan Song, MD, Luxiang Chi, MD, and Guoqiang Zhuang, PhD

Meeting Highlights

41st Annual Meeting of the American Society of Clinical Oncology

The authors discuss recent findings on anastrozole for the treatment of localized breast cancer, trastuzumab for HER2-positive metastatic breast cancer, zolendronic acid and bone density in women with breast cancer, gemcitabine for non–small cell lung cancer, oblimersen sodium for advanced malignant melanoma, bevacizumab for recurrent ovarian cancer, standard therapy plus oxaliplatin for colorectal cancer, lenalidomide for myelodysplastic syndromes, and raloxifene for endometrial cancer.
Lawrence M. Prescott, PhD, and Sharon L. Prescott

Meeting Highlights

158th Annual Meeting of the American Psychiatric Association

Mr. Alexander summarizes presentations on the relationship between paroxetine (Paxil®) and suicidal ideation, escitalopram (Lexapro®) for depression and comorbid anxiety, and a specialized form of methylphenidate HCl (OROS® MPH/Concerta®) for attention-deficit/hyperactivity disorder.
Walter Alexander, MS

Pharmaceutical-Approval Update

Dr. Goldenberg reviews exenatide injection (Byetta™) for diabetes, pregabalin (Lyrica™) for partial-onset seizures in adults with epilepsy, and tigecycline (Tygacil™) for skin and intra-abdominal infections.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial

Technology Assessment

David B. Nash, MD, MBA, describes the work performed at the University HealthSystem Consortium and the National Association of Public Hospitals in analyzing new biotechnology products.
David B. Nash, MD, MBA

Medication Errors

Benzocaine Topical Sprays and Methemoglobinemia

Matthew Grissinger, RPh, FASCP, discusses the incidence of life-threatening methemoglobinemia and its link with the use of topical anesthetic sprays containing benzocaine.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

FDA Reform Legislation to Move Forward Soon: Bills Emphasize Better FDA Evaluation and Surveillance

Stephen Barlas comments on pressure from Congress to improve the FDA’s post-marketing surveillance of drugs for life-threatening illnesses.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.

Drug Forecast

Eszopiclone (Lunesta™): A New Non-benzodiazepine Sedative–Hypnotic

Drs. Benjamin Chavez and Jose Rey review the benefits of eszopiclone (Lunesta™) for the treatment of insomnia.
Benjamin Chavez, PharmD, and Jose A. Rey, PharmD